Form 4: Arcellx Chief Medical Officer Reports Stock Transactions

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and stock options.

Summary

• Christopher Heery, the Chief Medical Officer of Arcellx, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 12, 2024, Heery exercised stock options to acquire 7,964 shares at $6.28 and 12,036 shares at $15.
• He also sold 19,918 shares at a weighted average price of $55.1297 and 82 shares at a weighted average price of $56.0334.
• Following these transactions, Heery directly owns 9,278 shares of common stock and holds options for 287,209 shares.
• The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan established on December 22, 2023.
• Heery also acquired 340 shares under the Issuer's 2022 Employee Stock Purchase Plan on May 14, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key personnel and their sentiment towards the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The Rule 10b5-1 trading plan is a common tool used by insiders to avoid accusations of trading on material non-public information, similar to practices at companies like Pfizer or Amgen where executives routinely use such plans.
• The vesting schedules described are typical for equity compensation plans in the biotech industry, aligning with practices seen at companies like Moderna or BioNTech.

Stakeholder Impact

• The transactions may influence investor perception of the company's stock, although the impact is likely to be minimal given the routine nature of the filing and the use of a pre-arranged trading plan.

Key Dates